{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:53:29Z","timestamp":1791183209432,"version":"4.1.0"},"reference-count":29,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:00:00Z","timestamp":1791072000000},"content-version":"vor","delay-in-days":276,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Case Reports in Dermatological Medicine"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by pruritic, scaly, erythematous lesions, xerosis, and lichenification. Dupilumab, a monoclonal antibody targeting I\u2010 (IL)\u20104 and IL\u201013 signaling, is widely used to treat moderate to severe AD. We report a 22 year\u2010old male with a history of asthma and chronic childhood AD who was started on dupilumab 300\u2009mg every 2\u2009weeks after multiple relapses despite topical therapy. Baseline Eczema Area and Severity Index (EASI), Dermatology Life Quality Index (DLQI), and Physician Global Assessment (PGA) scores were not recorded; however, the patient showed marked clinical improvement of his skin disease, with a posttreatment EASI score of 1. Five months after dupilumab initiation, he presented with palpitations and pleuritic chest pain. His absolute eosinophil count was 2070\u2009cells\/\u03bcL, increased from a pretreatment baseline of 860\u2009cells\/\u03bcL, with an elevated Troponin I of 1.56\u2009ng\/mL. Electrocardiography showed normal sinus rhythm. Cardiac magnetic resonance demonstrated myocardial edema, early gadolinium enhancement, and late gadolinium enhancement involving the interventricular septum and adjacent walls, confirming myocarditis. A comprehensive workup, including antinuclear antibody, antineutrophil cytoplasmic antibody, renal function, a respiratory viral PCR panel, stool ova and parasites, and whole exome sequencing, excluded autoimmune, infectious, and familial causes. Computed tomography of the sinuses demonstrated moderate rhinosinusitis without invasive features. A diagnosis of eosinophilic myocarditis secondary to dupilumab\u2010associated hypereosinophilia was made. Dupilumab was discontinued, and the patient was treated with corticosteroids and colchicine, with resolution of eosinophilia and symptoms. Although dupilumab\u2010associated eosinophilia is usually mild and transient, this case highlights the importance of maintaining a high index of suspicion for rare but serious organ involvement, particularly in patients with new cardiopulmonary symptoms or baseline eosinophilia, while recognizing that routine eosinophil monitoring is not currently recommended for all patients receiving dupilumab.<\/jats:p>","DOI":"10.1155\/crdm\/8570980","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:45:39Z","timestamp":1791182739000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hypereosinophilia With Organ Damage Secondary to Dupilumab Therapy: A Case Report and Literature Review"],"prefix":"10.1155","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7345-3700","authenticated-orcid":false,"given":"Manar","family":"Alotaibi","sequence":"first","affiliation":[{"name":"Department of Dermatology Prince Sultan Military Medical City  Riyadh Saudi Arabia  psmmc.med.sa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3812-774X","authenticated-orcid":false,"given":"Sadeem","family":"AlHelal","sequence":"additional","affiliation":[{"name":"College of Medicine Princess Nourah Bint Abdulrahman University  Riyadh Saudi Arabia  pnu.edu.sa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6779-9297","authenticated-orcid":false,"given":"Noura","family":"Alotaibi","sequence":"additional","affiliation":[{"name":"Department of Dermatology Prince Sultan Military Medical City  Riyadh Saudi Arabia  psmmc.med.sa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Alsudairy","sequence":"additional","affiliation":[{"name":"Department of Dermatology Prince Sultan Military Medical City  Riyadh Saudi Arabia  psmmc.med.sa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,4]]},"reference":[{"key":"e_1_2_9_1_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1361005"},{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2020.10.016"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1104a146"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0906"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.08.051"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2020-2-3"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17981"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.05.019"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2023.11.009"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-025-00952-w"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2024-3-5"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00048-2024"},{"key":"e_1_2_9_13_2","first-page":"386","article-title":"Eosinophilic Complications During Dupilumab Therapy for Type 2 Diseases: a Systematic Review","volume":"63","author":"Lazzeroni M.","year":"2025","journal-title":"Rhinology"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.2147\/jaa.s588165"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.77797"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12878"},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4624"},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.02.016"},{"key":"e_1_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.15844"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13954"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.123.031454"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12968-023-00979-0"},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.14740\/jmc5168"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15229"},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.4193\/rhin23.357"},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2311843"},{"key":"e_1_2_9_27_2","doi-asserted-by":"crossref","DOI":"10.1002\/cia2.12303","article-title":"Safety and Effectiveness of Dupilumab in the real-world Treatment of Atopic Dermatitis in Japan: 1-Year Interim Analysis from a Post-marketing Surveillance","author":"Saeki H.","year":"2023","journal-title":"Journal of Cutaneous Immunology and Allergy"},{"key":"e_1_2_9_28_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15041525"},{"key":"e_1_2_9_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.05.041"}],"container-title":["Case Reports in Dermatological Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/crdm\/8570980","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1155\/crdm\/8570980","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/crdm\/8570980","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:45:41Z","timestamp":1791182741000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/crdm\/8570980"}},"subtitle":[],"editor":[{"given":"Semonti","family":"Nandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1155\/crdm\/8570980"],"URL":"https:\/\/doi.org\/10.1155\/crdm\/8570980","archive":["Portico"],"relation":{},"ISSN":["2090-6463","2090-6471"],"issn-type":[{"value":"2090-6463","type":"print"},{"value":"2090-6471","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2026-04-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"8570980"}}